According to a recent study published in the Journal of Urology, men with localized prostate cancer on hormone therapy (ADT) have a significant increase in their risk for developing diabetes. In this retrospective study of 12,191 men with localized prostate cancer who did not have diabetes were followed once they went on ADT. It was [...]
JAMA Oncology has published a new study that suggests that adding a statin drug at the initiation of hormone therapy (ADT) to the treatment protocol for a man with progressive, hormone-sensitive prostate cancer may significantly impact their actual time to disease progression (TTP). Historically, we know Statin use has been associated with improved prostate cancer [...]
Starting androgen deprivation therapy (ADT) to treat advanced prostate cancer is usually the start of a long treatment period that will continue for many years, actually until you die. Since our goal in cancer treatment is to make cancer a chronic illness and since prostate cancer does progress for most men in a relatively slow [...]
Clinicians believe that there is an association between the risk of cardiovascular disease (CVD) and the duration and type of androgen-deprivation therapy (ADT) in men with prostate cancer. Researchers took data from 2006 to 2012 on filled drug prescriptions from the Swedish national health care registers. A cohort of 41,362 men with prostate cancer who were on ADT [...]
Last year after the ASCO meeting in Chicago I declared that there was one particular presentation of the CHAARTED trial that would be a game changer for the treatment of newly diagnosed men with very significant prostate cancer. The game changer was that men diagnosed with significant disease and who were still ADT naive (not [...]